Log In
BCIQ
Print this Print this
 

ASP-440

  Manage Alerts
Collapse Summary General Information
Company ActiveSite Pharmaceuticals Inc.
DescriptionSmall molecule plasma kallikrein inhibitor
Molecular Target Kallikrein
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetic macular edema (DME)
Indication DetailsTreat diabetic macular edema (DME)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today